Sysmex Corp
TSE:6869

Watchlist Manager
Sysmex Corp Logo
Sysmex Corp
TSE:6869
Watchlist
Price: 2 917 JPY -0.56% Market Closed
Market Cap: 1.8T JPY
Have any thoughts about
Sysmex Corp?
Write Note

Sysmex Corp
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sysmex Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Sysmex Corp
TSE:6869
PP&E Net
ÂĄ113.6B
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
7%
Terumo Corp
TSE:4543
PP&E Net
ÂĄ412.2B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
9%
Olympus Corp
TSE:7733
PP&E Net
ÂĄ249.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
6%
Nihon Kohden Corp
TSE:6849
PP&E Net
ÂĄ26B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
9%
JEOL Ltd
TSE:6951
PP&E Net
ÂĄ22.4B
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
6%
Fukuda Denshi Co Ltd
TSE:6960
PP&E Net
ÂĄ53.5B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
9%
No Stocks Found

Sysmex Corp
Glance View

Market Cap
1.8T JPY
Industry
Health Care

In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care. Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.

Intrinsic Value
3 013.24 JPY
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Sysmex Corp's PP&E Net?
PP&E Net
113.6B JPY

Based on the financial report for Sep 30, 2024, Sysmex Corp's PP&E Net amounts to 113.6B JPY.

What is Sysmex Corp's PP&E Net growth rate?
PP&E Net CAGR 10Y
7%

Over the last year, the PP&E Net growth was 4%. The average annual PP&E Net growth rates for Sysmex Corp have been 6% over the past three years , 3% over the past five years , and 7% over the past ten years .

Back to Top